Thursday was a rough session for big tech and a wild one for the bottom of the market. The Nasdaq tumbled about 2.6% as Meta and SpaceX sank, yet a China-operating oilfield-equipment maker rocketed 63.5% and a handful of micro-caps moved 5% to 40% after the bell. Here are 10 stocks under $3 to watch tomorrow, all smaller names that none of our recent watchlists covered. A caution up front: these are among the thinnest, riskiest stocks in the market, and where final closing prices were not available we say so and show after-hours quotes instead.
Stocks Under $3 to Watch Tomorrow: Thursday’s Market Snapshot
| Metric | Thursday Reading |
|---|---|
| S&P 500 | About -1.2% |
| Nasdaq Composite | About -2.6% |
| Dow Jones Industrial Average | Little changed |
| Meta | About -7% after results and a 2-for-1 split plan |
| Tesla | About -3% despite a better-than-expected quarter |
| SpaceX (SPCX) | About -9% |
| Treasury yields | Lower as investors rotated into bonds |
The Nasdaq tumbled about 2.6% as semiconductor stocks fell and worries over the AI trade grew, reversing Wednesday’s gains. TNN has followed the volatility in SpaceX shares since the June AI-stock rotation. Exact closing index levels were not confirmed at press time. Healthcare Services Group, Pool and Spotify rose on earnings, but the real action for our list came in small caps and after-hours trading.
Data note: Except for STAK, final Thursday closes were not available. “After-hours” prices come from Benzinga’s Thursday after-market lists, and “est. close” means the close implied by the after-hours price and percentage move. Fields we could not verify are marked “not confirmed.” RSI and MACD are omitted because feeds were stale. Support and resistance levels are analytical zones built from verified prices, implied closes and round numbers, not guaranteed targets. These stocks are speculative, and several have market values under $20 million.
1. STAK Inc. (STAK) | Close $1.64 (+63.5%) | The Oilfield-Equipment Maker With an AI-Power Dream
A 63% Single-Day Spike in a Stock With a 1.25 Million-Share Float
STAK led U.S. gainers on Thursday, jumping 63.5% to $1.64, the same day it published fiscal 2026 results.
| Metric | Value |
|---|---|
| Last Close | $1.64 (+63.5%); prior close ~$1.00 (est.) |
| 52-Week Range | $0.29 – $9.50 (per Tiger Brokers; date not shown) |
| Market Cap | ~$31M at $1.64 (est.; ~19.2M shares) |
| P/E / Dividend | Negative (EPS about -$0.48) / None |
| Volume vs. Average | Not confirmed |
| Float | ~1.25M shares |
| H1 FY2026 | Revenue $19.2M (+13.4%); gross margin 27.2%; net income $1.8M |
| Support 1 / 2 / 3 | $1.64 / $1.00 / $0.29 |
| Resistance 1 / 2 / 3 | $2.36 / $4.05 / $4.99 |
Catalyst & Latest News: We could not verify what drove Thursday’s spike beyond the earnings release. STAK, a Cayman-incorporated, China-operating maker of specialized oilfield vehicles, spiked as much as 278% on July 24, triggering four Nasdaq volatility halts, with no new filing behind the move. The company had announced plans in June for a U.S. subsidiary focused on AI data-center power.
Technicals: The stock has repeatedly spiked and faded. It closed at $2.36 in May, then fell nearly 39% after hours on first-half results, and the July spike peaked near $4.99.
Fundamentals: The dual-class structure gives Class B shares 30 votes each, concentrating control with insiders, and a January 2026 financing added six million shares.
Bull Case: Profitable on a small base, growing revenue and a tiny float that can squeeze higher. Bear Case: A history of violent reversals, concentrated insider control and no verified catalyst for Thursday.
What to Watch:
- A hold of $1.64 at the open
- The earnings release details and any financing
- Whether volume stays elevated
Forecast: Given the pattern, a gap-and-fade is the base case. A hold above $1.64 keeps $2.36 in reach, while a slide under $1.00 would erase the move.
Why This Matters: STAK is a classic low-float spike where liquidity, not fundamentals, drives the tape.
2. Kodiak AI (KDK) | Est. Close ~$1.04 | The Driverless-Truck Stock That Fell From $9 to $1
A $245 Million Market Value, a 37% Slide in Three Weeks and a Fresh Low in Sight
Kodiak AI traded at $1.08 after hours Thursday, up 3.8%, with a market value near $245 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $1.08 (+3.84%); est. close ~$1.04 |
| Oct. 2 Close | $1.64 (-1.8%); October range $1.58 – $1.95 (as of Oct. 2) |
| 52-Week Range | Not confirmed; earlier cited range $5.43 – $11.35 |
| Market Cap | ~$245M (after-hours) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed; older average ~765K shares |
| Analyst View | Consensus target ~$11.14 (Sept. 9, stale); one downgrade in the month to Oct. 2 |
| Support 1 / 2 / 3 | $1.04 / $1.00 / $0.80 |
| Resistance 1 / 2 / 3 | $1.08 / $1.58 / $1.64 |
Catalyst & Latest News: AAII’s tracker showed the stock at $1.64 on October 2 with one analyst downgrade over the prior month. Company headlines include a Bosch hardware agreement and a collaboration with General Dynamics Land Systems. We did not find a specific trigger for Thursday’s drop.
Technicals: Monthly closes slid from $4.35 in July to $3.78 in August, $1.92 in September and $1.59 so far in October, so the stock has lost roughly 88% from its January 2026 level (about $9.11).
Fundamentals: Kodiak went public through a SPAC merger in September 2025 at about $9.50 a share. Its model charges trucking companies per mile or per vehicle, and it reported a $34 million adjusted loss in its first quarter as a public company.
Bull Case: Strategic partnerships, a federal autonomous-truck bill in the headlines and analyst targets far above the price. Bear Case: Heavy cash burn (about $147M of negative free cash flow over the trailing year per Benzinga), a persistent downtrend and no verified catalyst.
What to Watch:
- A hold of $1.00
- Analyst reactions and any financing news
- A reclaim of $1.58, the October low
Forecast: Bounces should meet resistance near $1.58. A close under $1.00 would put $0.80 in play.
Why This Matters: KDK shows how quickly a SPAC-era growth story can reprice.
3. Lucid Diagnostics (LUCD) | Est. Close ~$0.32 | After-Hours +41.9% to $0.46
A Cancer-Screening Name Rockets 42% After the Bell From a Fraction of Its July Price
Lucid Diagnostics surged 41.9% to $0.46 after hours with a market cap near $67 million. We could not confirm the reason.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $0.46 (+41.9%); est. close ~$0.32 |
| Late-July Quote | ~$0.87 (after-hours, July 24) |
| 52-Week Range | $0.86 – $1.63 as of July; the stock is now below that range |
| Market Cap | ~$67M (after-hours) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Buy ratings from BTIG and Needham (older, with a $3 target from Needham) |
| Cash | $34.7M at Dec. 31, 2025 |
| Support 1 / 2 / 3 | $0.32 / $0.25 / $0.20 |
| Resistance 1 / 2 / 3 | $0.46 / $0.87 / $1.00 |
Catalyst & Latest News: Lucid is the majority-owned subsidiary of PAVmed, and both rose after hours Thursday. Its EsoGuard esophageal DNA test has Medicare support, but we could not verify a new headline for Thursday.
Technicals: The stock traded near $0.87 in late July with a $183 million market cap, so the after-hours price implies a decline of more than 60% since then.
Fundamentals: All revenue comes from the EsoGuard diagnostic test, and cash was $34.7M at year-end 2025.
Bull Case: A large screening market and Medicare coverage. Bear Case: A steep slide, a sub-$0.50 price that raises exchange-listing questions, and repeated equity raises.
What to Watch:
- Any company press release explaining the move
- A hold of $0.32
- Nasdaq minimum-bid notices
Forecast: After-hours spikes of 40%+ in sub-$1 stocks often fade. A hold above $0.32 keeps $0.46 in view, while a slip below it would erase the gain.
Why This Matters: LUCD is a deep-discount diagnostics story where the headline matters more than the chart.
4. PAVmed (PAVM) | Est. Close ~$2.05 | After-Hours +6.8% to $2.19
The Parent of Lucid Diagnostics Rises With Its Subsidiary
PAVmed rose 6.82% to $2.19 after hours, with a market cap near $22 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $2.19 (+6.82%); est. close ~$2.05 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$22M (after-hours) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $2.05 / $1.75 / $1.50 |
| Resistance 1 / 2 / 3 | $2.19 / $2.50 / $3.00 |
Catalyst & Latest News: PAVmed majority-owns Lucid Diagnostics, so Lucid’s after-hours jump likely lifted the parent. We did not verify a separate PAVmed announcement.
Technicals: The levels are round-number zones anchored on the implied close and the after-hours quote.
Fundamentals: We did not verify PAVmed’s latest financial figures for this article.
Bull Case: Exposure to Lucid’s upside through a low-priced parent. Bear Case: A market value near $22 million, no verified news and dependence on Lucid’s fortunes.
What to Watch:
- Lucid’s after-hours move at the open
- A hold of $2.05
- Any financing news
Forecast: If Lucid holds its gain, PAVM could reach $2.50. A fade in Lucid would likely pull PAVM back toward $1.75.
Why This Matters: PAVM is a derivative play whose direction follows its subsidiary.
5. Roadzen (RDZN) | Est. Close ~$1.13 | After-Hours -6.1% to $1.06
A $90 Million Tech Name Slips After the Bell
Roadzen fell 6.13% to $1.06 after hours with a market cap near $90 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $1.06 (-6.13%); est. close ~$1.13 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$90M (after-hours) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $1.00 / $0.90 / $0.75 |
| Resistance 1 / 2 / 3 | $1.13 / $1.25 / $1.50 |
Catalyst & Latest News: We did not verify a company announcement behind the after-hours decline.
Technicals: The stock sits right above the $1.00 level that matters for Nasdaq listing compliance, so $1.00 is the key support.
Fundamentals: Benzinga lists Roadzen in its information-technology movers. We did not verify revenue, cash or guidance figures.
Bull Case: A market value near $90 million with a stock close to $1. Bear Case: A sub-$1.10 price, no verified news and listing-compliance risk if it closes under $1.
What to Watch:
- A hold of $1.00
- Any press release or filing
- Volume at the open
Forecast: A hold above $1.00 limits the damage, while a close below it would raise bid-price concerns.
Why This Matters: RDZN is a reminder that the $1 line is a hard psychological and regulatory boundary.
6. NeuroOne Medical Technologies (NMTC) | Est. Close ~$0.98 | After-Hours +7.1% to $1.05
A Sub-$1 Medtech Name Pops Above the Line After the Bell
NeuroOne rose 7.14% to $1.05 after hours, with a market cap near $9 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $1.05 (+7.14%); est. close ~$0.98 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$8.9M (after-hours, per Benzinga) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $0.98 / $0.85 / $0.70 |
| Resistance 1 / 2 / 3 | $1.05 / $1.25 / $1.50 |
Catalyst & Latest News: We did not verify a company announcement for Thursday’s move.
Technicals: A move back above $1.00 matters for listing compliance, and the after-hours price clears that level.
Fundamentals: We did not verify NeuroOne’s financials for this article.
Bull Case: A reclaim of $1.00 on any follow-through. Bear Case: A very small market value, no verified catalyst and the chance of a fade at the open.
What to Watch:
- Whether the stock holds above $1.00
- Any press release
- Dilution risk
Forecast: A close above $1.00 would ease listing pressure. A fade below $0.98 would erase the move.
Why This Matters: NMTC shows how a few cents decide a micro-cap’s compliance story.
7. Estrella Immunopharma (ESLA) | Est. Close ~$0.72 | After-Hours +6.4% to $0.77
A $17 Million Biotech Edges Higher After Hours
Estrella rose 6.41% to $0.77 after hours, with a market cap near $17 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $0.77 (+6.41%); est. close ~$0.72 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$17.3M (after-hours) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $0.72 / $0.60 / $0.50 |
| Resistance 1 / 2 / 3 | $0.77 / $1.00 / $1.25 |
Catalyst & Latest News: We did not verify a company announcement behind the after-hours move.
Technicals: The stock is trading below $1, so a return above that mark is the main technical goal.
Fundamentals: Benzinga lists Estrella among its health-care movers. We did not verify pipeline or cash figures.
Bull Case: A low-priced biotech with a small market cap. Bear Case: No verified news, a sub-$1 price and likely dilution.
What to Watch:
- A hold of $0.72
- Any trial or financing update
- Nasdaq compliance notices
Forecast: Without a catalyst, expect the bid to fade. A move above $0.77 would need follow-through volume.
Why This Matters: ESLA is one of many sub-$1 biotechs where a compliance deadline can matter as much as a trial.
8. Longeveron (LGVN) | Est. Close ~$1.59 | After-Hours -6.3% to $1.49
A Tiny Biotech Slips After the Bell
Longeveron fell 6.3% to $1.49 after hours, with a market cap near $4.7 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $1.49 (-6.3%); est. close ~$1.59 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$4.7M (after-hours, per Benzinga) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $1.49 / $1.25 / $1.00 |
| Resistance 1 / 2 / 3 | $1.59 / $1.75 / $2.00 |
Catalyst & Latest News: We did not verify a company announcement behind the decline.
Technicals: The after-hours price sits below the implied close, so $1.59 becomes the first resistance.
Fundamentals: Benzinga lists Longeveron in its health-care movers. We did not verify financial or trial details.
Bull Case: A very small market value can make any positive headline move the stock. Bear Case: No verified news and a tiny, illiquid float.
What to Watch:
- A hold of $1.49
- Any clinical or financing update
- Volume at the open
Forecast: A reclaim of $1.59 would calm the setup. A break below $1.25 would suggest the slide has further to run.
Why This Matters: LGVN shows how thin a micro-cap’s market can be.
9. The Generation Essentials Group (TGE) | Est. Close ~$0.75 | After-Hours +9.3% to $0.82
A $42 Million Industrial Name Gains After the Bell
The Generation Essentials Group rose 9.34% to $0.82 after hours, with a market cap near $42 million.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $0.82 (+9.34%); est. close ~$0.75 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$41.8M (after-hours) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $0.75 / $0.65 / $0.50 |
| Resistance 1 / 2 / 3 | $0.82 / $1.00 / $1.25 |
Catalyst & Latest News: We did not verify a company announcement behind the after-hours gain.
Technicals: The stock trades below $1, so a reclaim of that level is the main goal.
Fundamentals: Benzinga lists the company among its industrials movers. We did not verify financial figures.
Bull Case: A sub-$1 industrial name with a bid after hours. Bear Case: No verified news and a price under the $1 line.
What to Watch:
- A hold of $0.75
- Any press release
- A push toward $1.00
Forecast: A close above $0.82 would confirm follow-through. A fade under $0.75 would erase the move.
Why This Matters: TGE is a watch-list name, not a conviction idea, until the company explains the move.
10. Our Bond (OBAI) | Est. Close ~$2.37 | After-Hours -11.8% to $2.09
A $3 Million Micro-Cap Slides After Its 1-for-20 Reverse Split
Our Bond fell 11.82% to $2.09 after hours, with a market cap near $3.4 million, days after its 1-for-20 reverse split took effect on October 19.
| Metric | Value |
|---|---|
| After-Hours (Oct 22) | $2.09 (-11.82%); est. close ~$2.37 |
| Reverse Split | 1-for-20, effective Oct. 19, 2026 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$3.4M (after-hours) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not confirmed |
| Analyst View | Not confirmed |
| Support 1 / 2 / 3 | $2.00 / $1.75 / $1.50 |
| Resistance 1 / 2 / 3 | $2.37 / $2.75 / $3.00 |
Catalyst & Latest News: OBAI was on the October 19 reverse-split calendar. TNN’s penny-stock coverage explains why post-split fades are common.
Technicals: A stock that falls double digits within days of a reverse split is showing the usual post-split pressure.
Fundamentals: We did not verify OBAI’s financial figures for this article.
Bull Case: A reset price and a very small market value. Bear Case: A fresh reverse split, a drop of nearly 12% after hours and no verified catalyst.
What to Watch:
- A hold of $2.00
- Any new financing
- Volume trend after the split
Forecast: Post-split names often keep sliding. A break under $2.00 would target $1.75.
Why This Matters: OBAI is a live example of what happens after a reverse split.
Stocks Under $3 to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Risk appetite split sharply on Thursday. Large-cap tech sold off on AI-trade worries, but the smallest stocks saw outsized swings in both directions: STAK’s 63.5% spike, Lucid’s 42% after-hours jump and Our Bond’s near-12% drop. Healthcare micro-caps dominated the after-hours gainers, while autonomous-trucking name Kodiak AI continued its slide. Most of these stocks have no verified catalyst, which is itself a warning: spikes without news tend to fade. Our forecast for Friday is volatile and headline-driven, with a weak Nasdaq setup likely to pressure speculative names at the open.
At a Glance: Stocks Under $3 to Watch Tomorrow (Oct 23, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | STAK | $1.64 close | +63.5% | FY2026 results; low float | $1.00 / $2.36 |
| 2 | KDK | ~$1.04 est. (AH $1.08) | +3.8% AH | Slide from $1.64 on Oct. 2 | $1.00 / $1.58 |
| 3 | LUCD | ~$0.32 est. (AH $0.46) | +41.9% AH | Unverified; PAVM subsidiary | $0.32 / $0.46 |
| 4 | PAVM | ~$2.05 est. (AH $2.19) | +6.8% AH | Follows Lucid | $2.05 / $2.50 |
| 5 | RDZN | ~$1.13 est. (AH $1.06) | -6.1% AH | Near $1 line | $1.00 / $1.13 |
| 6 | NMTC | ~$0.98 est. (AH $1.05) | +7.1% AH | Back above $1 | $0.98 / $1.25 |
| 7 | ESLA | ~$0.72 est. (AH $0.77) | +6.4% AH | Unverified | $0.72 / $1.00 |
| 8 | LGVN | ~$1.59 est. (AH $1.49) | -6.3% AH | Unverified | $1.49 / $1.59 |
| 9 | TGE | ~$0.75 est. (AH $0.82) | +9.3% AH | Unverified | $0.75 / $1.00 |
| 10 | OBAI | ~$2.37 est. (AH $2.09) | -11.8% AH | Post reverse-split slide | $2.00 / $2.37 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and micro-cap, sub-$1, clinical-stage and other high-volatility stocks carry elevated risk, including delisting and dilution. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change, particularly after-hours quotes. Several prices are after-hours quotes or estimates implied from reported percentage moves, and fields marked “not confirmed” were not verified. Support and resistance levels are analytical reference zones, not guaranteed price targets. Always complete independent due diligence prior to executing equity trades.
About The Author
